Gallbladder

Stubborn Digestion Issues? PLAMECA Can Help

Retrieved on: 
Wednesday, March 27, 2024
Diagnosis, Ginger, Esophagus, Gastrointestinal tract, Extrapyramidal system, GERD, Gallbladder, Cancer, Irritable bowel syndrome, Crohn's disease, Quality of life, Great Way Government, Hiatal hernia, Pancreas, IBS, Lactose intolerance, Stomach, Liver, Digestion, Animal feed

FORT LAUDERDALE, Fla., March 27, 2024 /PRNewswire/ -- There are many kinds of digestional disorders. Some are severe, while others are minor (yet uncomfortable) inconveniences. For those managing ongoing digestional discomfort, PLAMECA's Digestissimoh! offers clean, safe, and effective relief.

Key Points: 
  • Is a Great Way to Lighten Digestion Across the Board
    FORT LAUDERDALE, Fla., March 27, 2024 /PRNewswire/ -- There are many kinds of digestional disorders.
  • supplement is a perfect example of a safe, natural, and effective way to manage stubborn digestive issues over time," Fernández explains.
  • uses natural ingredients such as ginger, digestive enzymes, and marine coral to lighten digestion.
  • offers a safe, effective, natural way to lighten their digestion and keep things functioning on a day-to-day basis.

A Global Milestone in Innovative Pancreatic Cancer Therapy

Retrieved on: 
Thursday, March 7, 2024
Bangladesh Technical Education Board, Cancer, Cachexia, Toxicity, Anemia, Multimedia, Cell proliferation, NIH, Molecular biology, Pancreatic cancer, FDA, Quality of life, Animal, Drug development, Growth, Gallbladder, Metastasis, Nausea, Peripheral neuropathy, Argyreia nervosa, Lung, Breast, Stomach, Life expectancy, Leukemia, Patient, Paclitaxel, Survival, Diagnosis, Research, BGX, Biochemistry, Pharmaceutical industry

TAIPEI, March 6, 2024 /PRNewswire/ -- BioGate Precision Medicine Corp., a member of Powerchip Group, held a press conference today to unveil an innovative breakthrough in pancreatic cancer drug development. Dr. Frank Huang, Chairman and CEO of BioGate, revealed that BioGate through in-house R&D has created a targeted therapy biologic, BGX. This was achieved by developing multi-platform technology combining biochemistry, immunology, and molecular biology. Studies of animals implanted with human pancreatic cancer cells confirm BGX's efficacy in inhibiting tumor growth and antiproliferation in metastasis, while extending survival rates. This achievement represents a major global milestone in pancreatic cancer treatment. BioGate also announced its plan to apply for TFDA Phase I clinical trials and to seek approval from the U.S. FDA, offering hope and improved care for pancreatic cancer patients in Taiwan region as well as worldwide.

Key Points: 
  • Suppression of pancreatic cancer and increased survival rates in animals implanted with human pancreatic cancer cells when treated with biologic agent BGX, a proprietary targeted therapy developed in-house by BioGate.
  • Studies of animals implanted with human pancreatic cancer cells confirm BGX's efficacy in inhibiting tumor growth and antiproliferation in metastasis, while extending survival rates.
  • This achievement represents a major global milestone in pancreatic cancer treatment.
  • In studies of animals implanted with human cancer cells, BGX successfully inhibited the growth and spread of pancreatic cancer cells and prolonged survival rates.

A Global Milestone in Innovative Pancreatic Cancer Therapy

Retrieved on: 
Thursday, March 7, 2024
Bangladesh Technical Education Board, Cancer, Cachexia, Toxicity, Anemia, Cell proliferation, NIH, Molecular biology, Pancreatic cancer, FDA, Quality of life, Animal, Drug development, Growth, Gallbladder, Metastasis, Nausea, Peripheral neuropathy, Argyreia nervosa, Lung, Breast, Stomach, Life expectancy, Leukemia, Patient, Paclitaxel, Survival, Diagnosis, Research, BGX, Biochemistry, Pharmaceutical industry

TAIPEI, March 7, 2024 /PRNewswire/ -- BioGate Precision Medicine Corp., a member of Powerchip Group, held a press conference today to unveil an innovative breakthrough in pancreatic cancer drug development. Dr. Frank Huang, Chairman and CEO of BioGate, revealed that BioGate through in-house R&D has created a targeted therapy biologic, BGX. This was achieved by developing multi-platform technology combining biochemistry, immunology, and molecular biology. Studies of animals implanted with human pancreatic cancer cells confirm BGX's efficacy in inhibiting tumor growth and antiproliferation in metastasis, while extending survival rates. This achievement represents a major global milestone in pancreatic cancer treatment. BioGate also announced its plan to apply for TFDA Phase I clinical trials and to seek approval from the U.S. FDA, offering hope and improved care for pancreatic cancer patients in Taiwan region as well as worldwide.

Key Points: 
  • Suppression of pancreatic cancer and increased survival rates in animals implanted with human pancreatic cancer cells when treated with biologic agent BGX, a proprietary targeted therapy developed in-house by BioGate.
  • Studies of animals implanted with human pancreatic cancer cells confirm BGX's efficacy in inhibiting tumor growth and antiproliferation in metastasis, while extending survival rates.
  • This achievement represents a major global milestone in pancreatic cancer treatment.
  • In studies of animals implanted with human cancer cells, BGX successfully inhibited the growth and spread of pancreatic cancer cells and prolonged survival rates.

Canon Medical Systems and Olympus Announce Business Alliance regarding Endoscopic Ultrasound Systems

Retrieved on: 
Monday, January 15, 2024
Oncology, Health, Medical Devices, Technology, Manufacturing, Other Manufacturing, Hardware, Life, Bile, Aplio, Pancreatic cancer, Philosophy, Canon Medical Systems Corporation, Amplitude, Patient, Olympus Corporation, ERCP, MRI, Diagnosis, Attention, Intervention, Gallbladder, Google Images, History, EUS, Jaundice, SMI, Neurosurgery, Endoscopy, Liver, Marketing, Stomach, Duodenum, Pancreas, Physician, Medical imaging

Canon Medical Systems Corporation (Canon Medical) and Olympus Corporation (Olympus), today announced that we have reached an agreement to collaborate on Endoscopic Ultrasound Systems.

Key Points: 
  • Canon Medical Systems Corporation (Canon Medical) and Olympus Corporation (Olympus), today announced that we have reached an agreement to collaborate on Endoscopic Ultrasound Systems.
  • Canon Medical will develop and manufacture diagnostic ultrasound systems used in Endoscopic Ultrasonography1 (EUS), and Olympus will perform the sales and marketing efforts.
  • Canon Medical has a history of more than 100 years in the diagnostic imaging systems business, including X-ray diagnostic systems, CT, MRI, and ultrasound diagnostic systems, and provides products and services to more than 150 countries and regions worldwide.
  • In the field of EUS, diagnostic ultrasound systems are very important, and we are pleased to have a cooperative relationship with Canon Medical, which has advanced ultrasound imaging technology.

EndoSound® Receives 510(k) Clearance for Breakthrough EVS® Innovation, a novel Endoscopic Ultrasound (EUS) technology

Retrieved on: 
Tuesday, January 2, 2024
Medical Devices, FDA, Health, Health Technology, Clinical Trials, General Health, Liver, Inc., Ecosystem, Gallbladder, ASC, Patient safety, Pancreas, Tissue, Therapy, GI, EVS, Infection, EUS, Patient, Safety, Medical device

The EVS is a novel endoscopic ultrasound (EUS) device that attaches to upper gastrointestinal endoscopes.

Key Points: 
  • The EVS is a novel endoscopic ultrasound (EUS) device that attaches to upper gastrointestinal endoscopes.
  • "We are thrilled to receive 510(k) clearance for our EVS, a testament to the dedication and innovation of the entire EndoSound team.
  • Endoscopic Ultrasound (EUS) is a minimally invasive procedure performed to assess diseases of the GI tract and other nearby organs and tissues.
  • EndoSound is dedicated to expanding access to endoscopic ultrasound technology around the world.

Levita® Magnetics Announces First International Deployment of MARS™ Surgical System

Retrieved on: 
Thursday, December 7, 2023
Medicine, Prostate, Surgeon, Cleveland Clinic, Patient, FDA, Gallbladder, Magnet, Cholecystectomy, Weight loss, Magnetism, Hospital, Dentistry, Medical imaging, MARS

MOUNTAIN VIEW, Calif., Dec. 7, 2023 /PRNewswire/ -- Levita Magnetics, whose mission is to help more patients get access to better surgery, announced today the international launch of its MARS surgical system at Hospital Luis Tisne in Santiago, Chile. This marks another milestone in the global advancement of minimally invasive surgery.

Key Points: 
  • Dr. Julio Jimenez at the Hospital Luis Tisne performed a series of procedures, including same-day discharge gallbladder removals and bariatric surgeries.
  • This deployment of the MARS system comes shortly after the company's first commercial use cases in the United States at the world-renowned Cleveland Clinic.
  • "The deployment of the MARS surgical system in Hospital Luis Tisne, an important public hospital in Santiago, Chile, marks a moment of pride for our entire team.
  • We will continue to push paradigm-shifting solutions across medicine in the coming months through our clinically valuable, cost and space-efficient surgical system."

With Obesity on the Rise, New Bariatric Study Finds Surgeons Don't Follow the Same Best Practices, Even Within the Same Hospital

Retrieved on: 
Monday, November 20, 2023
Sleeve gastrectomy, PALO, Research, Entrepreneurship, Weight loss, Dean (education), Liver, Risk, Surgeon, Insurance, Patient, Cleveland Clinic, Most, Threat Intelligence Platform, OP, Pancreas, Rectum, Obesity, American College, Educational technology, Gallbladder, Uterus, Hospital, Innovation, News, Bariatric surgery, Health, Operation Time, Health insurance, Dentistry, Medical device

PALO ALTO, Calif., Nov. 20, 2023 /PRNewswire/ -- Theator, a leading AI driven health-technology company, today announced the findings of its in-depth analysis on bariatric surgery. Coinciding with news of insurance companies continuing to refuse coverage of GLP-1 drugs for weight loss and obesity associated with a yearly excess of $1,861 in health costs per person, Theator set out to gather insights into how longer lasting solutions like bariatric surgeries were stacking up across the board. 

Key Points: 
  • While 82% of procedures reinforced the staple line, 18% did not; which can lead to complications.
  • Theator's data analysis also highlighted that surgeons across systems do not follow the same protocols.
  • While many of these metrics were previously unknown, Theator revealed that on average it took surgeons 13.2 minutes to conduct the gastric transection step.
  • Most recently, Theator's Surgical Intelligence Platform was recognized by Fast Company as part of their annual list of Most Innovative Companies for 2023.

Karmanos Cancer Institute first to receive new FDA-approved treatment for advanced liver cancer

Retrieved on: 
Monday, November 13, 2023
Prostate, Breast, Brain, Research, FACP, Physician, Disease, Liver cancer, Radio, Patient, FDA, Karmanos Cancer Institute, Gallbladder, Tongue, National Comprehensive Cancer Network, Cancer, Survival, Growth, HCC, Field line, Quality of life, Gastrointestinal tract, Life, Karmanos, McLaren Health Care Corporation, Medical imaging, Pharmaceutical industry

DETROIT, Nov. 13, 2023 /PRNewswire/ -- Karmanos Cancer Institute, the largest provider of cancer care and research in Michigan and part of McLaren Health Care, announced today that it will be the first provider in the country to offer patients the new FDA-approved TheraBionic P1 device for the treatment of advanced hepatocellular carcinoma (HCC), the most common type of liver cancer. HCC accounts for approximately 90% of all liver cancers, with average survival rates between 6 and 20 months. The innovative TheraBionic P1 device is a novel at-home treatment that emits low levels of radio-frequency electromagnetic fields that block the growth of tumor cells without affecting healthy tissue. The device is approved for treating patients 18 years of age or older who fail first- and second-line therapies.

Key Points: 
  • HCC accounts for approximately 90% of all liver cancers, with average survival rates between 6 and 20 months.
  • The innovative TheraBionic P1 device is a novel at-home treatment that emits low levels of radio-frequency electromagnetic fields that block the growth of tumor cells without affecting healthy tissue.
  • The device is approved for treating patients 18 years of age or older who fail first- and second-line therapies.
  • "Often, patients with advanced hepatocellular carcinoma who fail first- and second-line therapies have severely impaired liver function, so additional treatment options are limited or nonexistent.

Top Gastroenterology and Liver Disease Specialist, Dr. David P. Yamini, Receives Castle Connolly's 2023 Top Doctor® Award

Retrieved on: 
Thursday, November 9, 2023
Hepatology, Irritable bowel syndrome, Disorder, American Gastroenterological Association, Stomach, Esophagus, ERCP, IBS, Liver, American College of Gastroenterology, Liver disease, Internal medicine, Indigestion, Patient, Multimedia, Gastrointestinal Endoscopy, Human, Santa Monica Boulevard, Castle Connolly Medical, Cedars-Sinai Medical Center, Pancreas, American College, Ulcerative colitis, Gallbladder, Crohn's disease, Gastroenterology, University, SIBO, Physician, Inflammatory bowel disease, Castle, Nursing, Film industry

BEVERLY HILLS, Calif., Nov. 9, 2023 /PRNewswire-PRWeb/ -- Dr. David Yamini has been selected as a 2023 Top Doctor® by Castle Connolly. Dr. Yamini is an accomplished physician who is double board-certified in gastroenterology and internal medicine. He serves patients in Santa Monica and Beverly Hills, CA, treating diseases and disorders of the digestive system. Dr. Yamini's medical education, training, hospital appointments and disciplinary history were rigorously screened by the Castle Connolly physician-led research team. Castle Connolly publishes its list of Top Doctors at http://www.castleconnolly.com and in a wide variety of partner publications, magazines and affiliate websites. Around 7% of the nation's top board-certified, licensed physicians have been selected as Castle Connolly Top Doctors in their regions for their specialties. Individuals do not and cannot pay to be selected as a Castle Connolly Top Doctor. Dr. David Yamini offers advanced diagnostic and therapeutic procedures and has established a reputation as one of the best Los Angeles gastroenterologists and liver disease specialists. Dr. Yamini offers expertise in issues involving the digestive tract, biliary system, liver and pancreas, with a proficiency in endoscopic retrograde cholangiopancreatography (ERCP). He takes a comprehensive approach to diagnosing and treating patients with all types of gastrointestinal (GI) problems and disorders that affect the small and large intestine, stomach, esophagus, gallbladder, liver and pancreas, including inflammatory bowel disease (Crohn's, ulcerative colitis), indigestion (dyspepsia), small intestinal bacterial overgrowth (SIBO) and irritable bowel syndrome (IBS). Dr. Yamini provides his patients with a superior level of compassionate and attentive personalized care.

Key Points: 
  • BEVERLY HILLS, Calif., Nov. 9, 2023 /PRNewswire-PRWeb/ -- Dr. David Yamini has been selected as a 2023 Top Doctor® by Castle Connolly.
  • Dr. Yamini's medical education, training, hospital appointments and disciplinary history were rigorously screened by the Castle Connolly physician-led research team.
  • Dr. David Yamini offers advanced diagnostic and therapeutic procedures and has established a reputation as one of the best Los Angeles gastroenterologists and liver disease specialists .
  • "It is such an honor to be recognized by my peers for this award," says Dr. David Yamini.

Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics

Retrieved on: 
Tuesday, September 5, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, HSR, Hart–Scott–Rodino Antitrust Improvements Act, CTX, Gallbladder, Asset purchase agreement, Jay Traver, Liver disease, Medication, Acquisition, DSM-IV codes, Patient, Rare, Therapy, Pharmaceutical industry, Spiroplasma mirum, Cholic acid

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) and Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the completion of Mirum’s previously announced acquisition of Travere’s bile acid product portfolio that includes Cholbam® (cholic acid) and Chenodal® (chenodiol), two medications addressing rare diseases in high-need settings (the “Asset Purchase”).

Key Points: 
  • Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) and Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the completion of Mirum’s previously announced acquisition of Travere’s bile acid product portfolio that includes Cholbam® (cholic acid) and Chenodal® (chenodiol), two medications addressing rare diseases in high-need settings (the “Asset Purchase”).
  • In connection with the closing of the Asset Purchase, Travere received an upfront payment of $210 million from Mirum, and remains eligible to receive up to $235 million in potential sales-based milestone payments.
  • The closing of the Asset Purchase was subject to the satisfaction of customary closing conditions, including the expiration of the waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976.
  • In connection with the closing, Travere will provide certain transitional services to Mirum.